Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia)

N/A

Report date: 2022/10/20 16:38:38

Base Information

Drug NameAnti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia)

Drug Alias Name抗CD3 /人源化3F8双特异性抗体活化的T淋巴细胞-弗吉尼亚大学anti-CD3 x hu3F8 bispecific antibody-armed ATCHu3F8Bi-armed ATCOKT3/humanized 3F8 bispecific antibody-activated T lymphocytesGD2Bi-aATC +[7]

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionAnti-GD2Anti-CD3

TargetsDisialoganglioside GD2T cell surface glycoprotein CD3

Therapy Area/IndicationsNeuroblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Virginia

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Virginia

Inactive CompaniesN/A

Active IndicationsNeuroblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A